🔎 Trials Near Me

Beranda › Kanker Ginjal (Karsinoma Sel Renal) › California

Uji klinis Kanker Ginjal (Karsinoma Sel Renal) di California

51 studi untuk Kanker Ginjal (Karsinoma Sel Renal) mencari peserta di lokasi di California.

Kota di California

Teks studi resmi (Bahasa Inggris)

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  • Research Site, San Diego
  • Research Site, Santa Monica
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT05536141

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

  • NEO-811 Los Angeles Site, Duarte
  • NEO-811 San Diego Site, San Diego
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT07300241

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

  • UCSF Medical Center at Mission Bay ( Site 5008), San Francisco
Menerima pesertaFase 1/2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07049926

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

  • University of California San Diego Moores Cancer Center, La Jolla
  • Cedars-Sinai Medical Center, Los Angeles
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06234605

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
  • PCR Oncology, Arroyo Grande
  • AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
  • dan 20 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #59, Santa Barbara
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05176483

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

  • University of California Irvine, Orange
  • Stanford, Palo Alto
  • University of California San Francisco, San Francisco
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05287945

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Keck Medicine of USC Koreatown, Los Angeles
  • Los Angeles General Medical Center, Los Angeles
  • USC / Norris Comprehensive Cancer Center, Los Angeles
  • dan 1 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT03866382

DESTINY-PANTUMOUR04

  • Research Site, San Diego
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • University of California San Diego, La Jolla
  • Stanford University, Palo Alto
  • UCLA Medical Center, Santa Monica
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04981119

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Precision NextGen Oncology, Beverly Hills
  • OPN Healthcare, Inc, Glendale
  • University of Southern California, Los Angeles
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06047379

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  • Local Institution - 0178, Palo Alto
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07293351

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

  • University of California San Diego, La Jolla
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06863311

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  • PCR Oncology, Arroyo Grande
  • Tower Cancer Research Foundation, Beverly Hills
  • Mills-Peninsula Medical Center, Burlingame
  • dan 16 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT05327686

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
  • City of Hope Investigational Drug Services (IDS), Duarte
  • UC San Diego Medical Center - Encinitas, Encinitas
  • dan 13 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07227415

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

  • USC Norris Comprehensive Cancer Center, Los Angeles
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT04969315

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

  • City of Hope Medical Center, Duarte
  • University of California San Diego Medical Center, Moores Cancer Center, La Jolla
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07195916

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • University of California, San Diego, La Jolla
  • Hoag Memorial Hospital Presbyterian, Newport Beach
  • Redwood City, Redwood City
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  • Sutter Auburn Faith Hospital, Auburn
  • Tower Cancer Research Foundation, Beverly Hills
  • City of Hope Comprehensive Cancer Center, Duarte
  • dan 23 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06661720

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

  • City of Hope Medical Center, Duarte
  • City of Hope at Irvine Lennar, Irvine
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT05830058

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • University of Southern California, Los Angeles
  • Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
  • Cedars-Sanai Medical Center, Los Angeles
  • dan 1 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT06582017

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

  • UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06432036

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

  • City of Hope National Medical Center, Duarte
  • Chao Family Comprehensive Cancer Center, Orange
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT05361720

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  • Community Cancer Institute, Clovis
  • USC/Norris Comprehensive Cancer Center, Los Angeles
  • Hoag Memorial Hospital Presbyterian, Newport Beach
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT04895709

A Study of MGC026 in Participants With Advanced Solid Tumors

  • The Angeles Clinic and Research Institute, Los Angeles
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT06242470

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

  • City of Hope Medical Center, Duarte
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT07226544

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

  • Providence Medical Foundation ( Site 0141), Fullerton
  • USC Norris Comprehensive Cancer Center ( Site 0126), Los Angeles
  • Cedars-Sinai Medical Center ( Site 0112), Los Angeles
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT07227402

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Duarte
  • Xencor Investigative Site, Sacramento
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT05433142

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • City of Hope, Duarte
  • Los Angeles Cancer Network, Glendale
  • California Research Institute, Los Angeles
  • dan 3 lainnya
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT04198766

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

  • University of California, San Francisco, San Francisco
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT07043608

Imaging of Solid Tumors Using 18F-TRX

  • University of California, San Francisco, San Francisco
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jul 2026 · NCT06942104

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

  • City of Hope Medical Center, Duarte
  • City of Hope Medical Center, Irvine
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT07128680

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  • John Wayne Cancer Institute (JWCI), Santa Monica
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT03972657

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

  • University of California, Davis, Sacramento
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06101290

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

  • Start Lacn, Los Angeles
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT07517198

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

  • City of Hope Medical Center, Duarte
  • City of Hope at Irvine Lennar, Irvine
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jun 2026 · NCT07037004

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

  • University of Southern California, Los Angeles
  • Cedars-Sinai Medical Center, Los Angeles
  • UCLA Department of Medicine, Los Angeles
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Jun 2026 · NCT06026410

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

  • City of Hope, Irvine
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mei 2026 · NCT06053658

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.